Our top pick for
Zogenix, Inc is a biotechnology business based in the US. Zogenix shares (ZGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Zogenix employs 141 staff and has a trailing 12-month revenue of around USD$7.1 million.
Since the stock market crash in March caused by coronavirus, Zogenix's share price has had significant negative movement.
Its last market close was USD$21.1, which is 30.04% down on its pre-crash value of USD$30.16 and 26.73% up on the lowest point reached during the March crash when the shares fell as low as USD$16.65.
If you had bought USD$1,000 worth of Zogenix shares at the start of February 2020, those shares would have been worth USD$407.11 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$418.41.
|Latest market close||USD$21.1|
|52-week range||USD$16.65 - USD$57.22|
|50-day moving average||USD$20.6163|
|200-day moving average||USD$24.4021|
|Wall St. target price||USD$47.82|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.32|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-30)||-1.03%|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$7.1 million|
|Gross profit TTM||USD$-111,991,000|
|Return on assets TTM||-24.93%|
|Return on equity TTM||-58.06%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 7.6 million Zogenix shares held short by investors – that's known as Zogenix's "short interest". This figure is 7.2% up from 7.1 million last month.
There are a few different ways that this level of interest in shorting Zogenix shares can be evaluated.
Zogenix's "short interest ratio" (SIR) is the quantity of Zogenix shares currently shorted divided by the average quantity of Zogenix shares traded daily (recently around 996864.29512516). Zogenix's SIR currently stands at 7.59. In other words for every 100,000 Zogenix shares traded daily on the market, roughly 7590 shares are currently held short.
However Zogenix's short interest can also be evaluated against the total number of Zogenix shares, or, against the total number of tradable Zogenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zogenix's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Zogenix shares in existence, roughly 130 shares are currently held short) or 0.1339% of the tradable shares (for every 100,000 tradable Zogenix shares, roughly 134 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zogenix.
Find out more about how you can short Zogenix stock.
We're not expecting Zogenix to pay a dividend over the next 12 months.
Zogenix's shares were split on a 1:8 basis on 1 July 2015. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zogenix shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Zogenix shares which in turn could have impacted Zogenix's share price.
Over the last 12 months, Zogenix's shares have ranged in value from as little as $16.65 up to $57.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zogenix's is 1.7368. This would suggest that Zogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.